Cost-Effectiveness Analysis of Pharmacogenomics (PGx)-Based Warfarin, Apixaban, and Rivaroxaban Versus Standard Warfarin for the Management of Atrial Fibrillation in Ontario, Canada.

Aneeka HafeezLauren E CiprianoRichard B KimGregory S ZaricUte I SchwarzSisira Sarma

Published in: PharmacoEconomics (2023)

We found that PGx-based warfarin for patients with AF is cost-effective at a WTP threshold of C$50,000/QALY. Apixaban had a higher probability of being cost-effective (> 50%) at a WTP threshold of C$93,000/QALY.

Keyphrases

atrial fibrillation
oral anticoagulants
direct oral anticoagulants
catheter ablation
left atrial
left atrial appendage
venous thromboembolism
heart failure
percutaneous coronary intervention
mitral valve
electronic health record